Dr. Tesha Monteith discusses growing evidence supporting CGRP-targeted therapies as first-line preventive treatment options for people with migraine. <span class= "dig-Text dig-Text--variant-paragraph dig-Text--size-small dig-Text--color-faint dig-18ip5q9d_24-12-0 dig-18ip5q90_24-12-0 dig-18ip5q9p_24-12-0 dig-18ip5q9s_24-12-0 dig-18ip5q9l_24-12-0 dig-18ip5q9w_24-12-0 dig-18ip5q9f_24-12-0 _transcriptCaptionText_uvr9k_85"> Show citation:  <span class= "dig-Text dig-Text--variant-paragraph dig-Text--size-small dig-Text--color-faint dig-18ip5q9d_24-12-0 dig-18ip5q90_24-12-0 dig-18ip5q9p_24-12-0 dig-18ip5q9s_24-12-0 dig-18ip5q9l_24-12-0 dig-18ip5q9w_24-12-0 dig-18ip5q9f_24-12-0 _transcriptCaptionText_uvr9k_85"> Reuter U, Dycke AV, Versijpt J, et al. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. Lancet Neurol. 2026;25(9):806-817. doi:<a href= "https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00214-0/fulltext" target="_blank" rel= "noopener">10.1016/S1474-4422(26)00214-0</a>

Optimizing Management of Episodic Cluster Headache

The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.